Literature DB >> 3888052

Neutrophil specific granule deficiency.

J I Gallin.   

Abstract

Neutrophil specific granules are thought to be important in the evolution of the inflammatory response. Specific granules are preferentially released with minor membrane perturbation in vitro or in vivo, and secreted products probably have important effects on humoral and cellular components of inflammation. In vitro studies reveal that some secreted specific granule products activate the complement cascade to generate the chemoattractant C5a and the opsonin C3b, while other secreted products are selectively chemotactic for monocytes. Translocation of receptors for chemoattractants (fmet-leu-phe) and opsonins (C3bi) from specific granules or closely related organelles to the plasma membrane may play an important role in chemotaxis, adherence, and phagocytosis. Similar translocation of constituents of the electron transport chain involved in the respiratory burst (i.e. cytochrome b) probably plays a role in neutrophil oxidative metabolism and hydrogen peroxide generation. In vivo and in vitro studies of neutrophils from patients with congenital specific granule deficiency, acquired specific granule deficiency (thermal injury and neonates), or normal neutrophils experimentally depleted of nuclei and organelles support these conclusions. Thus, release of specific granule constituents appears to be important for amplification of the initial and subsequent phases of the inflammatory response.

Entities:  

Mesh:

Year:  1985        PMID: 3888052     DOI: 10.1146/annurev.me.36.020185.001403

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  13 in total

Review 1.  The molecular pathology of primary immunodeficiencies.

Authors:  Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  J Mol Diagn       Date:  2004-05       Impact factor: 5.568

2.  Intractable diarrhoea of infancy caused by neutrophil specific granule deficiency and cured by stem cell transplantation.

Authors:  R F Wynn; M Sood; K Theilgaard-Mönch; C J Jones; A F Gombart; M Gharib; H P Koeffler; N Borregaard; P D Arkwright
Journal:  Gut       Date:  2006-02       Impact factor: 23.059

3.  Chédiak-Higashi syndrome neutrophils are characterized by the absence of both normal azurophilic granules.

Authors:  B C West
Journal:  Am J Pathol       Date:  1986-01       Impact factor: 4.307

4.  Neutrophil enzyme activities in carrageenan-induced inflammation in rats.

Authors:  I Sopata; E Wojtecka-Lukasik; J Wize; S Maśliński
Journal:  Agents Actions       Date:  1989-08

5.  Selective defect in myeloid cell lactoferrin gene expression in neutrophil specific granule deficiency.

Authors:  K J Lomax; J I Gallin; D Rotrosen; G D Raphael; M A Kaliner; E J Benz; L A Boxer; H L Malech
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

6.  Microbicidal/cytotoxic proteins of neutrophils are deficient in two disorders: Chediak-Higashi syndrome and "specific" granule deficiency.

Authors:  T Ganz; J A Metcalf; J I Gallin; L A Boxer; R I Lehrer
Journal:  J Clin Invest       Date:  1988-08       Impact factor: 14.808

7.  Neutrophil degranulation inhibits potential hydroxyl-radical formation. Relative impact of myeloperoxidase and lactoferrin release on hydroxyl-radical production by iron-supplemented neutrophils assessed by spin-trapping techniques.

Authors:  B E Britigan; D J Hassett; G M Rosen; D R Hamill; M S Cohen
Journal:  Biochem J       Date:  1989-12-01       Impact factor: 3.857

Review 8.  Infections in patients with inherited defects in phagocytic function.

Authors:  Timothy Andrews; Kathleen E Sullivan
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

9.  Heparin binding protein (CAP37) is an opsonin for Staphylococcus aureus and increases phagocytosis in monocytes.

Authors:  M Heinzelmann; A Platz; H Flodgaard; F N Miller
Journal:  Inflammation       Date:  1998-10       Impact factor: 4.092

10.  CAP37, a human neutrophil-derived chemotactic factor with monocyte specific activity.

Authors:  H A Pereira; W M Shafer; J Pohl; L E Martin; J K Spitznagel
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.